You may find more results for this query on our sister sites: 360Dx and Precision Oncology News.
Life Technologies has made a tender offer to acquire the remaining shares of Geneart that it does not already own for around €25.5 million. The total purchase price was approximately €56 million.
The acquisition adds Proxeon's portfolio of nanoflow liquid chromatography systems, columns, ion sources, and bioinformatics software to Thermo Fisher's existing proteomics offerings.
Silence said that as a result of the consolidation, it has laid off about 20 staffers, primarily in research and development.
The Australian firm has acquired, among other assets, the BrevaGen breast cancer risk test, which it expects to launch in the second half of this year.
The acquisition of Signature's diagnostic cytogenetic tests for genetic diseases will enhance PerkinElmer's molecular diagnostic testing portfolio.
"We believe [the FAP drug] is a product that the combined company could commercialize with a small specialty sales force [with] minimal sales and marketing infrastructure," MDRNA's President and CEO Michael French said this week.
The all-stock merger will combine the scientific informatics firms, with Accelrys CEO Max Carnecchia leading the merged entity.
The animal and food safety company Neogen bought the agricultural trait selection business to enhance its genomics-based diagnostics products.
Through the transaction, MDRNA will gain Cequent's orally delivered transkingdom RNAi technology, which involves using attenuated Escherichia coli to transcribe therapeutic shRNAs.
Luminex's acquisition of BSD Robotics will provide it with new technologies in automation and robotics in the field of dry sample handling.
New analyses indicate female researchers are publishing less during the coronavirus pandemic than male researchers, according to Nature News.
A study suggests people with the ApoE e4 genotype may be more likely to have severe COVID-19 than those with other genotypes, the Guardian says.
Direct-to-consumer genetic testing companies are searching for a genetic reason for why some people, but not others, become gravely ill with COVID-19, the Detroit Free Press reports.
In PNAS this week: forward genetics-base analysis of retinal development, interactions of T cell receptors with neoantigens in colorectal cancer, and more.